Although thiazolidinediones were designed as specific peroxisome proliferator-activated receptor (PPAR)-␥-ligands, there is evidence for some off-target effects mediated by a non-PPAR␥ mechanism. Previously we have shown that rosiglitazone has antiinflammatory actions not explicable by activation of PPAR␥,but possibly by the glucocorticoid receptor (GR). Rosiglitazone induces nuclear translocation both of GR-green fluorescent protein, and endogenous GR in HeLa and U20S cells but with slower kinetics than dexamethasone. Rosiglitazone also induces GR phosphorylation (Ser 211 ), a GR ligand-binding-specific effect. Rosiglitazone drives luciferase expression from a simple glucocorticoid-response element containing reporter gene in a GR-dependent manner (EC 50 4 M), with a similar amplitude response to the partial GR agonist RU486. Rosiglitazone also inhibits dexamethasone-driven reporter gene activity (IC 50 2.9 M) in a similar fashion to RU486, suggesting partial agonist activity. Importantly we demonstrate a similar effect in PPAR␥-null cells, suggesting both GR dependence and PPAR␥ independence. Rosiglitazone also activates a GAL4-GR chimera, driving a upstream activating sequence promoter, demonstrating DNA template sequence independence and furthermore enhanced steroid receptor coactivator-1-GR interaction, measured by a mammalian two-hybrid assay. Both ciglitazone and pioglitazone, structurally related to rosiglitazone, show similar effects on the GR. The antiproliferative effect of rosiglitazone is increased in U20S cells that overexpress GR, suggesting a biologically important GR-dependent component of rosiglitazone action. Rosiglitazone is a partial GR agonist, affecting GR activation and trafficking to influence engagement of target genes and affect cell function. This novel mode of action may explain some off-target effects observed in vivo. Additionally, antagonism of glucocorticoid action may contribute to the antidiabetic actions of rosiglitazone. (Endocrinology 150: 75-86, 2009) 
Although thiazolidinediones were designed as specific peroxisome proliferator-activated receptor (PPAR)-␥-ligands, there is evidence for some off-target effects mediated by a non-PPAR␥ mechanism. Previously we have shown that rosiglitazone has antiinflammatory actions not explicable by activation of PPAR␥,but possibly by the glucocorticoid receptor (GR). Rosiglitazone induces nuclear translocation both of GR-green fluorescent protein, and endogenous GR in HeLa and U20S cells but with slower kinetics than dexamethasone. Rosiglitazone also induces GR phosphorylation (Ser 211 ), a GR ligand-binding-specific effect. Rosiglitazone drives luciferase expression from a simple glucocorticoid-response element containing reporter gene in a GR-dependent manner (EC 50 4 M), with a similar amplitude response to the partial GR agonist RU486. Rosiglitazone also inhibits dexamethasone-driven reporter gene activity (IC 50 2.9 M) in a similar fashion to RU486, suggesting partial agonist activity. Importantly we demonstrate a similar effect in PPAR␥-null cells, suggesting both GR dependence and PPAR␥ independence. Rosiglitazone also activates a GAL4-GR chimera, driving a upstream activating sequence promoter, demonstrating DNA template sequence independence and furthermore enhanced steroid receptor coactivator-1-GR interaction, measured by a mammalian two-hybrid assay. Both ciglitazone and pioglitazone, structurally related to rosiglitazone, show similar effects on the GR. The antiproliferative effect of rosiglitazone is increased in U20S cells that overexpress GR, suggesting a biologically important GR-dependent component of rosiglitazone action. Rosiglitazone is a partial GR agonist, affecting GR activation and trafficking to influence engagement of target genes and affect cell function. This novel mode of action may explain some off-target effects observed in vivo. Additionally, antagonism of glucocorticoid action may contribute to the antidiabetic actions of rosiglitazone. (Endocrinology 150: 75-86, 2009) P eroxisome proliferator-activated receptors (PPARs) are nuclear receptors activated by binding endogenously produced fatty acids to regulate lipid homeostasis (1) . They are members of the nuclear receptor superfamily and heterodimerize on DNA with retinoid X receptor to regulate target gene expression (2) . PPAR␥ is highly expressed in adipocyte and macrophage in which it acts to influence differentiation, lipid storage, and glucose homeostasis (2) (3) (4) (5) . It is this activity that is exploited by synthetic PPAR␥ ligands, notably the thiazolidinediones, e.g. rosiglitazone, and pioglitazone, to improve insulin sensitivity (6 -10) . However, even though these drugs are in routine clinical use, their precise mode of action remains elusive because muscle is the major tissue responsible for insulin mediated glucose disposal, and PPAR␥ expression is very low in muscle (11) . A further mechanism of action is the repression of secreted molecules from fat, including TNF␣, which is known to induce insulin resistance (12) (13) (14) .
Thiazolidinediones, acting through PPAR␥, also act to influence differentiation of stem cells to direct differentiation into adipocytes at the expense of osteoblasts (2, 5, (15) (16) (17) (18) . This results in loss of mineralized bone mass, and there are reports of increased fracture risk in women. In one report there was a strik-ing 6% annual rate of bone loss, similar to that seen with glucocorticoids (19, 20) .
Although thiazolidinediones were designed as specific ligands for PPAR␥, there is evidence for some effects being mediated by a nonclassical, non-PPAR␥ mechanism (21) (22) (23) . In particular, there is evidence that high concentrations of PPAR␥ ligands are required to inhibit expression of proinflammatory cytokines and yet modulation of lipid metabolic genes, and differentiation of preadipocytes to adipocytes occurs with concentrations of ligand orders of magnitude lower, close to the measured Kd for binding PPAR␥ (23) . Furthermore, in embryonic stem cells null for PPAR␥ induced to differentiate down the macrophage lineage treatment with PPAR␥ ligands, both endogenous (prostaglandin J2) and exogenous (thiazolidinediones) suppressed expression of proinflammatory cytokines including TNF, IL-1␤, IL-6, and enzymes inducible nitric oxide synthase and cyclooxygenase-2 (23). This effect is also typical of the response these cells have after glucocorticoid exposure (24, 25) . Glucocorticoids (Gcs) modulate cellular events after binding and activation of the ubiquitously expressed intracellular glucocorticoid receptor (GR) (24) . The GR is also a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors (24) .
In an inactive state, the GR resides in the cytoplasm as part of a multiprotein complex, which includes chaperone proteins and immunophilins (26 -28) . Ligand-activated GR is released from this complex and is then free to initiate nongenomic effects within the cytoplasm and can also translocate to the cell nucleus where it dimerizes and binds palindromic glucocorticoid-response elements (GREs). Once in the nucleus, the GR-GRE complex has the capacity to recruit either coactivator or corepressor molecules that can modify chromatin and either facilitate or inhibit transcription initiation (29 -33) .
Recently we showed that the antiinflammatory effects of the PPAR␥ ligands rosiglitazone and ciglitazone in vivo could be reversed by the GR antagonist RU486 and also that in vitro their actions in cell lines was dependent on expression of GR but not PPAR␥ (34) . To further analyze the potential activation of GR by exposure to PPAR␥ ligands, we have undertaken a detailed series of studies to show nuclear translocation of GR in response to rosiglitazone, accompanied by GR Ser 211 phosphorylation, a posttranslational modification seen rapidly after ligand activation of the GR. This was accompanied by rosiglitazone-mediated regulation of a GR reporter gene and recruitment of the steroid receptor coactivator (SRC)-1, in a GR expressionspecific and PPAR␥-independent manner. We were also able to show GR-dependent inhibition of osteoblast cell proliferation by rosiglitazone. Taken together this is strong evidence for rosiglitazone action through GR and may explain some of the spectrum of rosiglitazone activities observed in vivo. 
Materials and Methods

Immunofluorescence
After 24 h serum withdrawal, HeLa, PPAR (Ϫ/Ϫ ), or U20S cells transfected (Fugene 6; Roche Diagnostics, Burgess Hill, UK) with hGR-GFP were treated were treated as specified in Results. Cells were fixed with 4% paraformaldehyde (PFA) for 30 min at 4 C and then permeabilized (0.02% Triton X-100 in PBS) for 30 min at room temperature. Fixed cells were blocked (1% FCS in PBS) for 4 h at room temperature with agitation and then in primary antibody (1:200, diluted in blocking buffer) overnight at 4 C. After three 10-min washes in PBS, cells were incubated in secondary antibody (1:500, diluted in PBS) for 2 h. After three further 10-min washes, coverslips were mounted using vectashield hard set mountant containing the nuclear 4Ј,6Ј-diamino-2-phenylindole (DAPI) stain (Vector Laboratories, Peterborough, UK). Fluorescent cells were visualized using a C1 confocal microscope (Nikon, Tokyo, Japan; an upright 90i microscope with a ϫ60/1.40 Plan Apo objective; pinhole 30 m, scan speed 400 Hz unidirectional, format 1024 ϫ 1024). Images for DAPI, Alexa488, and Alexa546 were excited with the 405-, 488-, and 543-nm laser lines, respectively, as previously described (35) . One hundred cells from three independent experiments were scored for GR localization, whether GR was localized principally to the nucleus, cytoplasm, or distributed evenly between the two compartments.
Immunoblot analysis
Cell lysates (30 g protein) were electrophoresed on sodium dodecyl sulfate/acrylamide gels and transferred to 0.2-m nitrocellulose membranes (Bio-Rad Laboratories, Hertfordshire, UK) overnight at 4 C. Membranes were blocked for 6 h (0.15 M NaCl, 1% dried milk, 0.1% Tween 20) and incubated with primary antibodies (diluted in blocking buffer) overnight at 4 C. After three 10-min washes [88 mM Tris (pH 7.8), 0.25% dried milk, 0.1% Tween 20], membranes were incubated with a species-specific horseradish peroxidase-conjugated secondary antibody (diluted in wash buffer) for 1 h at room temperature and washed a further three times, each for 10 min. Immunoreactive proteins were visualized using enhanced chemiluminescence (ECL Advance; GE Healthcare), as previously described (35, 36) .
Reporter gene assay
Cells were cotransfected with 1 g TAT3-luciferase reporter gene construct together with 0.1 g cytomegalovirus-renilla luciferase (to correct for transfection efficiency) using Fugene 6. After 24 h serum withdrawal, cells were treated as specified in results before lysis and then assayed for luciferase activity using a dual-luciferase reporter assay system following the manufacturer's instructions (Promega, Southampton, UK) (37).
Mammalian one-and two-hybrid assays
Using a previously described method (29, 38) , cells were cotransfected with 5 g each of pG5-luc and either pBIND or pBINDGR-LBD (mammalian one hybrid assay) or 5 g each of pG5-luc and pACTGR-LBD together with pBIND, pBIND-SRC-1, or pBIND-NCoR [mammalian two hybrid (M2H) assay]. After 18 h ligand treatment (details specified in Results) cells were lysed, harvested, and assayed for luciferase activity using a dual-luciferase reporter assay system (Promega) following the manufacturer's instructions.
Proliferation assay
Cells were grown in DMEM supplemented with vehicle, dexamethasone, and/or rosiglitazone as indicated. Five days later, cells were trypsinized, aliquots seeded in 96-well plates, and cells allowed to adhere overnight. Cell numbers were calculated using a CellTiter96 AQueous cell proliferation assay system (Promega) following the manufacturer's instructions (36) .
Modeling of rosiglitazone docking
Binding modes of rosiglitazone in the GR-ligand-binding domain (LBD) were investigated using molecular docking calculations. The GR-LBD docking model was derived from the GR/deacylcortivazol (DAC) complex crystal structure (PDB code 3bqd) that was recently reported by Suino-Powell et al. (39) . The MOE software package was used to prepare the GR-LBD docking model (MOE 2007.0902; Chemical Computing Group Inc., Montréal, Canada): DAC and water oxygen atoms were deleted, hydrogen atoms were added to the protein residues, and the atomistic structure subjected to energy minimization using the Amber94 force-field option with constraints placed on nonhydrogen atoms. Molecular docking calculations of rosiglitazone were performed with the GOLD software package (GOLD 4.0; Cambridge Crystallographic Data Center, Cambridge, UK).
Results
GR translocates to the nucleus in the presence of rosiglitazone
GR undergoes ligand-dependent nuclear translocation to engage target genes. To assess nuclear translocation in response to rosiglitazone treatment the U20S cell line, which expresses low levels of GR detectable by immunofluoresence ( Fig. 1 ), was transfected with GR-GFP. After incubation with vehicle, 100 nM dexamethasone or 10 M rosiglitazone (times indicated), cells were analyzed for GR localization using a GR-specific antibody and also by the colocalization of the GFP tag. In untreated cells, the GR localizes predominantly to the cytoplasm (82 Ϯ 3%) or throughout the entire cell (16 Ϯ 3%), with few cells showing nuclear GR accumulation (2 Ϯ 1%) (Fig. 1, A and B) . Treatment with 100 nM dexamethasone induces near-complete nuclear translocation (98 Ϯ 2%) of GR by 30 min, which is sustained over the 120-min assay period. After incubation with rosiglitazone for 30 min, GR translocates into the nucleus in a significant proportion of cells (31 Ϯ 8% nuclear GR) and is found diffusely distributed throughout the cell in others (54 Ϯ 10%). The magnitude of GR translocation is further increased after 120 min rosiglitazone treatment (95 Ϯ 2% nuclear GR, Fig. 1, A and B) . GR translocation in response to 120 min treatment with rosiglitazone is almost as efficient as that seen in response to dexamethasone (rosiglitazone 95 Ϯ 2%; dexamethasone 98 Ϯ 2% nuclear GR). Vehicle treatment is without effect at each time point (data not shown).
Although overexpression of GFP-tagged GR is a very sensitive and specific bioassay for analysis of GR trafficking, it is recognized that overexpression of the GR can alter intracellular compartment segregation. To exclude this possibility, these studies were repeated in HeLa cells that express only endogenous GR (Fig. 2) . After 30 min exposure, dexamethasone treatment promotes near-complete translocation of GR (98 Ϯ 1% nuclear GR), and rosiglitazone treatment promotes a heterogeneous GR distribution (n Ͼ c, 44 Ϯ 11%; n ϭ c, 46 Ϯ 10%). Within 120 min, the rosiglitazone effect is close to that seen with dexamethasone ( Fig. 2, A and B, rosiglitazone 98 Ϯ 2%; dexamethasone 99 Ϯ 1% nuclear GR).
GR is phosphorylated after treatment with rosiglitazone
Within the cytoplasm, GR undergoes rapid ligand-dependent phosphorylation on Ser 211 (40) . To examine whether GR is phosphorylated after rosiglitazone treatment, HeLa and A549 cells were serum starved and treated with dexamethasone or rosiglitazone for times ranging from 30 min (Fig. 3A) to 4 h (Fig.  3B) . Cell extracts were analyzed for GR (Ser 211 ) phosphorylation and abundance by immunoblotting. Images in Fig. 3 demonstrate that GR is Ser 211 phosphorylated in response to treatment with dexamethasone and rosiglitazone in both HeLa and A549 cells.
Although GR is rapidly phosphorylated by either rosiglitazone or dexamethasone, the magnitude of effect after rosiglitazone is reduced in comparison. Interestingly, whereas treatment with dexamethasone clearly promotes both phosphorylation and down-regulation of GR (more evident in HeLa cells), rosiglitazone treatment only promotes GR Ser 211 phosphorylation (Fig. 3, A and B) .
Rosiglitazone-mediated TAT3-luc activation is dependent on GR expression
After nuclear translocation the GR binds to recognition sites on DNA to regulate transcription. Dexamethasone promotes a robust and easily measured induction of reporter gene expression in both HeLa and A549 cells (Fig. 4, A and B) . Rosiglitazone also induces target gene expression, although to a lesser extent. In comparison with dexamethasone, the dose-response curve for rosiglitazone is markedly right shifted. There is still, however, a highly significant induction of TAT3-luc in HeLa cells (34-fold induction, EC 50 Ͼ60 M) and a much smaller increase in A549 cells (4-fold induction, EC 50 24 M).
The decreased induction seen in A549 cells when compared with HeLa cells is compatible with the reduced induction of reporter genes seen with dexamethasone in these cell models (HeLa cells 127-fold induction, EC 50 0.6 nM; A549 cells 36-fold induction, EC 50 0.6 nM). This is also compatible with the much lower induction of GR Ser 211 phosphorylation in A549 cells (Fig. 3) . To gain additional evidence for the dependence of this transcriptional induction on the presence of the GR, the GR-deficient U20S cell line was used. In U20S cells, there is no induction of the transfected reporter gene until 1 nM dexamethasone and no induction of the reporter gene seen at all with rosiglitazone (Fig. 4C ). Higher concentrations of dexamethasone did induce the reporter gene, probably due to activation of low-level endogenous GR. After transfection of U20S cells with the human GR expression vector, there is a significant induction of reporter gene activity by 0.01 nM dexamethasone, indicating that this effect is dependent on transfected GR. In addition, transfected GR confers rosiglitazone responsiveness to the reporter gene ( Fig. 4C ; U20S pcDNA3 EC 50 Ͼ8 mM; U20S pcDNA3-hGR Ec50 4 M).
Rosiglitazone and RU486 inhibit dexamethasone-induced TAT3-luc activation
RU486 is a high-affinity partial agonist of the GR, causing nuclear translocation, Ser 211 phosphorylation, DNA binding, and inhibiting the actions of full agonists such as dexamethasone. Figure 5A demonstrates that RU486 effectively inhibits dexamethasone-but not rosiglitazone-induced TAT3-luc activity.
Graphs presented in Fig. 5 , A and B, further suggest that both rosiglitazone and RU486 activate the reporter gene to a similar extent, perhaps suggesting partial agonist activity for rosiglitazone.
Indeed, experiments demonstrate that rosiglitazone effectively inhibits the response to a saturating concentration of dexamethasone ( Fig. 5C ; dexa- 
GR activation by rosiglitazone is PPAR␥ independent
Because PPAR␥ is the target receptor for rosiglitazone, it is possible that activation of GR is an indirect downstream effect after PPAR␥ activation. To determine the requirement of PPAR␥ for the effect of rosiglitazone on GR, studies were also conducted in cells isolated from PPAR␥ knockout mice [PPAR␥ (Ϫ/Ϫ) ]. In line with experiments presented in Figs. 1-3 , data shown in Fig.  6 demonstrate nuclear translocation of endogenous GR (Fig. 6A) and Ser 211 phosphorylation (Fig. 6B ) in response to treatment with rosiglitazone .
Reporter gene assays in PPAR␥ (Ϫ/Ϫ) cells (Fig. 6C ) produced robust induction of TAT3-luc in response to rosiglitazone, which not only shows PPAR␥ independence but also GR expression dependence. Pretreatment with rosiglitazone also significantly impaired the response of PPAR␥ (Ϫ/Ϫ) cells to dexamethasone (Fig. 6, D and E) , further suggesting partial agonist activity.
Rosiglitazone also activates transcription through a GAL4-GR LBD chimera
As an indication of rosiglitazone binding, the ability of rosiglitazone to activate isolated GR LBD was explored using a mammalian one-hybrid assay system.
Rosiglitazone activates transcription through an isolated GR LBD, fused to a GAL4 DNA binding domain. In comparison with the 23.5-fold induction caused by dexamethasone treatment, RU486 and rosiglitazone produced only modest but significant induction at their respective maximal doses ( Fig. 7A ; RU486, 2.9-fold; rosiglitazone, 3.1-fold). Because data were collected in PPAR␥ (Ϫ/Ϫ) cells, this once again suggests PPAR␥ independence. Importantly, because only the GR-LBD and not full-length GR was used, this suggests that only the LBD is required for interaction with rosiglitazone and also that the rosiglitazone effect is independent of the DNA response element sequence.
Rosiglitazone recruits SRC-1 and nuclear receptor corepressor (NCoR) to the GR ligand binding domain
Recruitment of cofactors to GR is ligand specific. Using a mammalian two-hybrid (M2H) system, differential recruitment of coactivators after rosiglitazone treatment was examined.
M2H assays were conducted in HeLa cells using GR-LBD fused to VP16 and the nuclear receptor interaction domain of SRC-1 or NCoR fused to Gal4. Figure 7 shows that dexamethasone but not RU486 recruits SRC-1 to the GR-LBD (Fig. 7B ) and also that RU486 and not dexamethasone recruits NCoR to the GR-LBD (Fig. 7C) . Interestingly, treatment with rosiglitazone recruited both SRC-1 and NCoR to the GR, perhaps suggesting a function distinct from either dexamethasone or RU486. In both cases, vehicle treatment was without effect (data not shown).
M2H assays were also conducted in PPAR␥ (Ϫ/Ϫ) cells (Fig. 7D) . Interestingly, the magnitude of response to rosiglitazone was greater in the PPAR␥ fold), These data suggest not only that the isolated GR-LBD is sufficient to recruit coactivators in response to rosiglitazone but also that this effect does not require PPAR␥.
The antiproliferative effect of rosiglitazone is enhanced by GR overexpression
Both rosiglitazone and dexamethasone are potent inhibitors of cellular proliferation. To determine whether rosiglitazonemediated antiproliferative effects are attributable to activation of GR, cells were treated with various concentrations of dexamethasone or rosiglitazone or a combination of both for 5 d and analyzed for proliferation by MTS assay.
In HeLa (Fig. 8A ) and A549 (Fig. 8B ) cells, treatment with rosiglitazone reduces rates of proliferation. The effect is smaller than that observed with dexamethasone in both cases. Cotreatment with rosiglitazone alters the antiproliferative profile of dexamethasone, suggesting a modest inhibitory effect on Gc action.
In GR-deficient U20S cells, rosiglitazone has an antiproliferative effect (Fig. 8C) . However, because overexpression of GR increases this effect, this suggests that at least a component of the antiproliferative effect of rosiglitazone may be GR dependent. Once again, cotreatment with rosiglitazone impairs the antiproliferative effect compared with dexamethasone alone (Fig. 8C) . Because neither dexamethasone nor rosiglitazone had an antiproliferative effect in PPAR␥ (Ϫ/Ϫ) cells, even after overexpression of GR (data not shown), the requirement of PPAR␥ for the antiproliferative effect of rosiglitazone was not explored.
The structurally related compounds ciglitazone and pioglitazone also activate GR
The thiazolidinediones ciglitazone and pioglitazone share structural similarity with rosiglitazone. The effect of treatment with ciglitazone and pioglitazone on GR activity was examined. To also demonstrate PPAR␥ independence, experiments were conducted in the PPAR␥ (Ϫ/Ϫ) cells. Figure 9A shows significant nuclear GR accumulation after exposure to 10 M ciglitazone. In contrast, pioglitazone shows only marginal effects on GR nuclear translocation (Fig. 9A) during the 120-min assay period. Immunoblots demonstrate Ser 211 phosphorylation of endogenous GR in response to both ciglitazone (1-100 M) and pioglitazone (1-100 M) with comparable effects with rosiglitazone (Fig. 9B) .
In PPAR␥ (Ϫ/Ϫ) cells, treatment with either ciglitazone (Fig. 9C) or pioglitazone (Fig. 9D ) induced a significant increase in luciferase expression, with similar effects observed after rosiglitazone treatment. Expression of GR was required to generate this response and once again demonstrate both GR dependence and PPAR␥ independence for activation of TAT3-luc. Mammalian one-hybrid assays (Fig. 9E ) and M2H assays (Fig. 9F) in PPAR␥ (Ϫ/Ϫ) cells demonstrate that both ciglitazone and pioglitazone promote recruitment of cofactors including SRC-1 to GR-LBD. Whereas the effects are significantly lower than the response to dexamethasone, they are comparable with the rosiglitazone effect. Vehicle treatment was without effect (data not shown).
Modeling rosiglitazone binding to the GR
To explore the possible mode of rosiglitazone binding to the GR, a series of modeling experiments were performed. The highest ranked docking pose of rosiglitazone shares some similarities with the binding of DAC as observed in the crystal structure (Fig.  10) . In particular, the pyridine ring of rosiglitazone is positioned similarly to the phenyl ring of DAC, and the thiazole ring of rosiglitazone is positioned similarly to the hydroxyacetyl moiety of DAC to allow the carbonyl oxygen atom to form hydrogen bonding interaction with Asn564. In common with DAC, ros- iglitazone is in van der Waals contact with atoms of the following residues: Asn564, Gln642, Thr739, Tyr735, Arg611, Ala607, Leu608, Phe623, Gln570, Leu566, Gly567, Leu563, Met646, Phe749, Cys736, Ile747. and Met604. We note that in addition to the rosiglitazone binding mode that has just been described, we also observed lower ranked docking poses in which the rosiglitazone is reversed (e.g. in which the thiazole group of rosiglitazone overlaps with the phenyl ring of DAC), but these reverse modes do not appear to exhibit any specific hydrogen bonding interactions with the protein.
Discussion
Thiazolidinedione drugs are a significant advance in the treatment of diabetes and are thought principally to improve insulin sensitivity by activating PPAR␥ (11) . However, they also exert a number of other effects including inhibition of expression of proinflammatory cytokines, an apparent beneficial effect in inflammatory disease (including inflammatory bowel disease), inhibition of cell proliferation, and chemoprevention of cancer in carcinogen-treated animals but also induction of osteoporosis (19, 21, 23, 41) . In addition, there is concern that fluid retention mediated by thiazolidinediones may exacerbate congestive heart failure (42) . Understanding the spectrum of thiazolidinedione action may lead to either new molecules with increased specificity of action or the better use of those that already exist. To this end we comprehensively explored the potential role of the GR as mediator of some thiazolidinedione effects.
In a previous study, we investigated the possibility that PPAR␥ ligands may exert some effects via the GR based on observations that activation of both GR and PPAR␥ results in inhibition of similar spectrum of proinflammatory cytokines (34) . In our earlier work, we were able to show that thiazolidinediones exert a suppressive activity on proinflammatory cytokines in cells that lack PPAR␥ expression. Moreover, the effect appeared to be dependent on GR expression. We found similar results using ciglitazone, a different molecular structure in the same class, suggesting that it is a property of the thiazolidinedione class of drugs (34) . Accordingly, we set out to 1 (B and D) , or pBIND-NCoR (C) and then treated with dexamethasone, RU486, or rosiglitazone and analyzed for luciferase activity using a dual-luciferase assay system. Data represent fold induction over control treatment. Graphs (mean Ϯ SD) show one of at least two representative experiments performed in triplicate. Significant difference from control treatment is indicated (*, P Ͻ 0.05; ** P Ͻ 0.01).
explore a potential mediating role of the GR for some of the actions of thiazolidinediones.
Initial studies used both genetically modified cells that overexpress a fluorophore-tagged form of the GR or HeLa cells that express endogenous GR. Both show that rosiglitazone promotes significant nuclear GR translocation. Nuclear translocation of the GR occurs very rapidly after ligand activation and is a prerequisite for subsequent engagement of the GR with the genome and therefore regulation of target genes. Consistently we found that the rate of nuclear translocation in response to rosiglitazone was significantly slower when compared with those observed after dexamethasone treatment. After 30 min there was a heterogeneous appearance with approximately even distribution of the GR between nuclear and cytoplasmic compartments. By 120 min, GR compartmentalization after rosiglitazone treatment was indistinguishable from that seen after treatment with dexamethasone. Because both models of overexpressed GR and endogenous GR gave comparable data, this increases the confidence that the results are in fact biologically meaningful. Indeed, we previously found an induction in GR content in nuclear extracts prepared by subcellular fractionation and analyzed by immunoblotting, providing additional reassurance that the rosiglitazone-dependent translocation is a consistent and robust phenomenon (34) .
The most rapid observable phenomenon associated with activation of the GR is induction of phosphorylation of Ser 211 in the GR N-terminal domain (36, 43, 44 HeLa cells also showed a greater fold change in reporter gene activity after dexamethasone, fitting with their increased glucocorticoid sensitivity. Rosiglitazone activated the reporter gene in both cell lines, although the effect seen was again much greater in the HeLa cells. To determine whether the transcriptional effect was dependent on GR, we used U20S cells, which are deficient in GR expression. In these cells we were able to show that transfection of the GR resulted in a marked left shift of the dose response to dexamethasone and also that overexpression of GR was absolutely required to permit any rosiglitazone regulation of the reporter gene. It is also important to note that the reporter gene harbors idealized consensus GREs and no potential PPAR␥ binding sites and is therefore not regulated by PPAR␥.
Further analysis of the transcriptional effects of rosiglitazone mediated by the GR showed that whereas RU486 efficiently antagonized transactivation of the reporter gene by dexamethasone, it had no discernible effect on the rosiglitazone induction, although the maximal transactivation seen with the two molecules was similar. This suggested that they may have a similar mode of action as partial agonists. Indeed, both rosiglitazone and RU486 similarly inhibited the reporter gene activation seen with dexamethasone. This is important because opposition to glucocorticoid action in the liver is known to increase insulin sensitivity (45) .
Because previous reports suggested that rosiglitazone and other PPAR␥ ligands exert an antiproliferative effect, a phenomenon frequently observed in epithelial cells for glucocorticoids, we also examined the actions of rosiglitazone on proliferation using HeLa, A549, and U20S cells (2, 36, 41, 46 -48) . These data show a significant inhibition of proliferation seen in both HeLa and A549 cells, although the magnitude of effect is less than that seen with dexamethasone. In U20S cells, the inhibition of proliferation seen with glucocor- ticoids was exclusively dependent on expression of the GR, and we were also able to show that GR expression enhanced the antiproliferative effects of rosiglitazone. Although there was an inhibitory effect seen with rosiglitazone in the non-GR-expressing U20S cells, presumably mediated by a non-GR-dependent mechanism, this effect is clearly greater in cells transfected with the GR expression vector, indicating a mediating role for GR.
Studies using cells derived from PPAR␥-deficient mice [PPAR␥ (Ϫ/Ϫ) ] demonstrate that GR nuclear translocation, ser211 phosphorylation and TAT3-luc transactivation are both PPAR␥-independent and GR-dependent.
The effect of rosiglitazone on GR activation appeared greater in the PPAR␥ (Ϫ/Ϫ) cells compared with either HeLa or A549 cells, which is perhaps suggestive of competition between PPAR␥ and GR for rosiglitazone binding.
Glucocorticoids had no inhibitory effect on PPAR␥ (Ϫ/Ϫ) cells, even when GR was overexpressed, indicating that this cell type does not couple GR activation to the antiproliferative program. Consistent with the view that the antiproliferative effects of rosiglitazone are dependent on the GR, there was no inhibitory effect seen with rosiglitazone either.
We go on to show that two structurally related compounds ciglitazone and pioglitazone also promote nuclear GR translocation, ser 211 phosphorylation, TAT3-luc transactivation, and SRC-1 recruitment in a GR-dependent and PPAR␥-independent manner, which suggests that GR activation is a property of the entire class of drugs and not a characteristic specific for rosiglitazone. Interestingly, the overall potency of each compound across the series of experiments broadly correlates with their reported affinity for PPAR␥.
We show that only the isolated GR-LBD is sufficient for the rosiglitazone effect, suggesting direct binding to the GR-LBD. In our previous paper, we were unable to detect high-affinity binding of rosiglitazone to the GR (34) . However, at high concentrations rosiglitazone did compete with labeled dexamethasone for binding to the GR, suggesting a low-affinity interaction. These data, together with that from the M2H assays (which used only isolated GR-LBD) suggest it is possible that the mode of action of the PPAR␥ ligand rosiglitazone may be through direct interaction with GR. In further support of this hypothesis, we provide theoretical modeling evidence of rosiglitazone binding to the GR-LBD structure, which further supports direct binding of rosiglitazone to the GR. However, we cannot exclude the possibility that rosiglitazone and drugs of its class can activate the GR by an indirect mechanism: either inducing local synthesis of a GR ligand or being metabolized to an active molecule. But the effect observed is certainly independent of the conventional rosiglitazone receptor, PPAR␥.
Taken together, we now provide evidence that thiazolidinediones promote partial activation of the GR. Although rosiglitazone clearly promotes GR nuclear translocation and Ser 211 phosphorylation and weakly activates a simple reporter gene, it also powerfully inhibits Gc-mediated gene induction. Therefore, we propose that, like RU486, rosiglitazone is a partial GR agonist.
We have identified an unexpected mechanism for rosiglitazone action in human cells that may explain some of the activities of the drug observed in vivo that do not appear to be attributable to action via PPAR␥. We propose that this mechanism may be important for the design of new, more specific PPAR␥ ligands and also potentially may be exploited for new therapeutics targeting the GR itself. 
FIG. 9.
Ciglitazone and pioglitazone activate GR. PPAR␥ (Ϫ/Ϫ) cells were serum starved, treated with 1-100 M rosiglitazone, 1-100 M ciglitazone (Cigli), or 1-100 M pioglitazone (Pi) for 120 min and subjected to immunoblot analysis to assay for GR phosphorylation (A) and immunofluorescent microscopy to examine subcellular trafficking of endogenous GR (B; three representative fields are shown). PPAR␥ (Ϫ/Ϫ) cells transiently cotransfected with hGR and TAT3-luc were serum starved; treated with rosiglitazone (Rosi), ciglitazone (Cigli), or pioglitazone (Pi; 0.01-100 M) for 18 h; and subjected to luciferase assay as an indicator of GR activation (C and D). Data for PPAR␥ (Ϫ/Ϫ) and PPAR␥ (Ϫ/Ϫ) GR cells were obtained from the same experiment and are represented on different axes to aid comparison. PPAR␥ (Ϫ/Ϫ) cells were transfected with 5 g each of pG5-luc and either pBIND or pBIND-GRLBD (E) or with 5 g each of pG5-luc, pACT-GRLBD, and either pBIND or pBIND-SRC-1 (F); then treated with 1-100 M rosiglitazone, 1-100 M ciglitazone, or 1-100 M pioglitazone for 18 h; and analyzed for luciferase activity using a dualluciferase kit. Data represent fold induction over control treatment. Graphs (mean Ϯ SD) show one of at least two representative experiments performed in triplicate. EC 50 values were determined from pooled data. Significant difference from control treatment is indicated (*, P Ͻ 0.05; **, P Ͻ 0.01). 
